+

WO2006002064A3 - Anticorps inhibant l'activite du facteur des cellules souches et utilisation de ces derniers dans le traitement de l'asthme - Google Patents

Anticorps inhibant l'activite du facteur des cellules souches et utilisation de ces derniers dans le traitement de l'asthme Download PDF

Info

Publication number
WO2006002064A3
WO2006002064A3 PCT/US2005/021043 US2005021043W WO2006002064A3 WO 2006002064 A3 WO2006002064 A3 WO 2006002064A3 US 2005021043 W US2005021043 W US 2005021043W WO 2006002064 A3 WO2006002064 A3 WO 2006002064A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cell
cell factor
asthma
treatment
factor activity
Prior art date
Application number
PCT/US2005/021043
Other languages
English (en)
Other versions
WO2006002064A2 (fr
Inventor
Steven Neben
Toshihiko Takeuchi
Adrian Tomkinson
Kathy Delaria
Kelly Yan
Teresa Wong
Malinda Longphre
Original Assignee
Aerovance Inc
Steven Neben
Toshihiko Takeuchi
Adrian Tomkinson
Kathy Delaria
Kelly Yan
Teresa Wong
Malinda Longphre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/867,506 external-priority patent/US20050112698A1/en
Application filed by Aerovance Inc, Steven Neben, Toshihiko Takeuchi, Adrian Tomkinson, Kathy Delaria, Kelly Yan, Teresa Wong, Malinda Longphre filed Critical Aerovance Inc
Publication of WO2006002064A2 publication Critical patent/WO2006002064A2/fr
Publication of WO2006002064A3 publication Critical patent/WO2006002064A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps humains qui sont dirigés spécifiquement contre le facteur des cellules souches contenant au moins un CDR provenant d'une bibliothèque combinatoire d'anticorps. Cette invention se rapporte également à des compositions pharmaceutiques comprenant les anticorps et des méthodes de traitement de l'asthme, ainsi que des méthodes de détection du facteur des cellules souches au moyen des anticorps.
PCT/US2005/021043 2004-06-14 2005-06-14 Anticorps inhibant l'activite du facteur des cellules souches et utilisation de ces derniers dans le traitement de l'asthme WO2006002064A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57946204P 2004-06-14 2004-06-14
US10/867,506 2004-06-14
US60/579,462 2004-06-14
US10/867,506 US20050112698A1 (en) 2001-12-17 2004-06-14 Antibody inhibiting stem cell factor activity and use for treatment of asthma

Publications (2)

Publication Number Publication Date
WO2006002064A2 WO2006002064A2 (fr) 2006-01-05
WO2006002064A3 true WO2006002064A3 (fr) 2006-08-31

Family

ID=35782258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021043 WO2006002064A2 (fr) 2004-06-14 2005-06-14 Anticorps inhibant l'activite du facteur des cellules souches et utilisation de ces derniers dans le traitement de l'asthme

Country Status (1)

Country Link
WO (1) WO2006002064A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017204125B1 (en) 2016-06-17 2017-10-26 Crispr Therapeutics Ag Compositions and methods for the depletion of cd117+ cells
AU2022237556A1 (en) * 2021-03-17 2023-09-28 Opsidio, LLC Stem cell factor antibodies and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194405A1 (en) * 2001-12-17 2003-10-16 Toshihiko Takeuchi Antibody inhibiting stem cell factor activity and use for treatment of asthma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194405A1 (en) * 2001-12-17 2003-10-16 Toshihiko Takeuchi Antibody inhibiting stem cell factor activity and use for treatment of asthma

Also Published As

Publication number Publication date
WO2006002064A2 (fr) 2006-01-05

Similar Documents

Publication Publication Date Title
WO2003051311A3 (fr) Anticorps inhibant l'activite du facteur de cellule souche et utilisation dans le traitement de l'asthme
WO2006026759A3 (fr) Antagonistes anti-beta7 humanises et utilisations de ceux-ci
WO2005030121A3 (fr) Composes, compositions et procedes
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
WO2005068503A3 (fr) Anticorps monoclonal specifique du m-csf et ses utilisations
AU2003285926A8 (en) Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
EP1599213A4 (fr) Translocation par membrane cellulaire d'inhibiteurs snare r gul s, compositions associ es et proc d s de traitement de pathologies
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
WO2007035489A3 (fr) Methodes de traitement ou de prevention du cancer au moyen d'agents de radiosensibilisation a base de pyridine carboxaldehyde pyridine thiosemicarbazone
HK1213782A1 (zh) 在診斷和治療類風濕性關節炎中使用的包含抗- 單克隆抗體的藥物組合物
GB2464652B (en) Improved methods for the generation of hepatocyte-like cells from human blastocyst-derived stem (hBS)
WO2003010291A3 (fr) Traitement de troubles concernant les cellules immunitaires et les cellules b
WO2006031926A3 (fr) Procedes d'isolation et d'expansion de lymphocytes t regulateurs derives du sang du cordon ombilical
WO2004033666A3 (fr) Procedes et composes pour inhiber l'activite de hec1 dans le traitement des maladies proliferatives
WO2006071812A3 (fr) Inhibiteur de complexe de platine iv
EP1742654A4 (fr) Anticorps anti-lfl2 pour le diagnostic, le pronostic et le traitement d'un cancer
WO2004037198A3 (fr) Induction de la mort de cellules tumorales provoquee par un anticorps
WO2006002064A3 (fr) Anticorps inhibant l'activite du facteur des cellules souches et utilisation de ces derniers dans le traitement de l'asthme
WO2005098444A3 (fr) Transporteurs de monocarboxylate exprimes dans des cellules cancereuses
TW200508249A (en) Antibodies for the cancer specific antigen
WO2006078776A3 (fr) Inhibiteurs et procedes de traitement de maladies cardio-vasculaires, et procede pour l'identification d'inhibiteurs
WO2006012222A3 (fr) Methodes de traitement de troubles des cellules de muscles lisses
WO2003099209A3 (fr) Compositions et procedes pour la recherche systematique et l'identification d'agents anti-vhc
WO2006056031A8 (fr) Utilisation d'ions ferreux pour augmenter l'immunoreactivite de preparations d'immunoglobuline
WO2005114107A3 (fr) Utilisation d'un anticorps monoclonal se liant specifiquement a des cellules souches

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05786139

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载